Cerus Corporation
As of Oct 22, 2026, Cerus is in Stage 3, the topping phase, now in week 6 (since Sep 14, 2026). It closed at $2.31, 29.6% below its 52-week high and below its 200-day average, which is rising.
Cerus Corporation operates as a biomedical products company. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CERS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CERS among Medical Devices19th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …19 | CERS | Stage 3 · wk 6 | 82 | −11.2% |
Cerus: quick answers
What stage is Cerus in?
As of Oct 22, 2026, Cerus (CERS) is in Stage 3, the topping phase. It entered Stage 3 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Cerus in an uptrend?
Its uptrend has stalled. Cerus is in Stage 3, the topping phase that follows an advance. It trades 5.6% below its 200-day average, which is rising.
How far is Cerus from its 52-week high?
Cerus closed at $2.31 on Oct 22, 2026, 29.6% below its 52-week high of $3.28. Its 52-week low is $1.40.
How has Cerus performed over the past year?
As of Oct 22, 2026, Cerus is up 40.9% over the past year and up 17.3% so far in 2026.
Which sector and industry is Cerus in?
Cerus is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.